Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2005
12/21/2005CN1709505A Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine
12/21/2005CN1232537C Heavy chain variable region single domain antibody reinforced fusion protein VH-LDP-AE
12/21/2005CN1232304C Functional fragment antigen of tetanus toxin and tetanus vaccine
12/20/2005US6977245 Oligodeoxynucleotide and its use to induce an immune response
12/20/2005US6977240 Methods of using the OB receptor antibodies to treat bodyweight disorders
12/20/2005US6977176 live vector vaccine; removal of sole dependence on catalytic balanced lethal maintenance systems; plasmid partition system prevents random segregation; enhanced inheritance and stability; genetic engineering; antibiotic resistance
12/20/2005US6977158 Mammalian IAP gene family, primers, probes, and detection methods
12/20/2005US6977079 Avian pneumovirus vaccine
12/20/2005US6977078 Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
12/20/2005US6977076 Immunomoderators; high molecular weight polysaccharides
12/20/2005US6977074 to an antigen by sustained release to the lymphatic system; cytotoxic T lymphocytes; immunization; drug delivery
12/20/2005US6977073 Method for stimulating an immune response
12/20/2005US6977072 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells
12/20/2005US6977070 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
12/20/2005US6977069 Contain at least two M. tuberculosis antigens; for vaccines, diagnosis, treatment
12/20/2005CA2321610C C-myc coding region determinant-binding protein (crd-bp)
12/20/2005CA2266319C Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
12/15/2005WO2005118886A2 Stable peptide mimetic of hiv gp41 fusion intermediate
12/15/2005WO2005118864A2 Antibodies and related molecules that bind to psca proteins
12/15/2005WO2005118840A2 Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
12/15/2005WO2005118813A2 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
12/15/2005WO2005118811A1 Novel polypeptide useful for diagnosis and treatment of cancer
12/15/2005WO2005118788A2 Novel artificial antigen presenting cells and uses therefor
12/15/2005WO2005118644A2 Binding molecules capable of neutralizing rabies virus and uses thereof
12/15/2005WO2005118643A2 Antibodies to angiogenesis inhibiting domains of cd148
12/15/2005WO2005118631A1 Novel protein complex and use thereof
12/15/2005WO2005118626A2 Peptides for inducing a ctl and/or htl response to hepatitis c virus
12/15/2005WO2005118615A1 Inhibitors of regiii proteins as asthma therapeutics
12/15/2005WO2005117988A1 Antibody colour pigment conjugates for changing eye color appearance
12/15/2005WO2005117986A2 Antibody drug conjugates and methods
12/15/2005WO2005117978A2 Method for treating multiple sclerosis
12/15/2005WO2005117977A2 Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
12/15/2005WO2005117976A2 Method of increasing radiation sensitivity by inhibition of beta one integrin
12/15/2005WO2005117975A2 Methods for treating vascular disease
12/15/2005WO2005117974A2 Cancer treatment method by inhibiting mage gene expression or function
12/15/2005WO2005117973A2 Bispecific binding agents for modulating biological activity
12/15/2005WO2005117972A2 Preventing autoimmune disease by using an anti-cd20 antibody
12/15/2005WO2005117971A2 Regulators of angiogenesis
12/15/2005WO2005117970A2 Antibodies of angiogenesis inhibiting domains of cd148
12/15/2005WO2005117969A2 Solution phase biopanning method using engineered decoy proteins
12/15/2005WO2005117968A2 Compositions and methods comprising an egfl7 antagonist for modulating vascular development
12/15/2005WO2005117967A2 Anti-il-9 antibody formulations and uses thereof
12/15/2005WO2005117966A1 Method to reduce hepatotoxicity of fas-mediated apoptosis-inducing agents
12/15/2005WO2005117965A1 Methods for preparing immunogenic conjugates
12/15/2005WO2005117964A2 Cynomolgus prostate specific antigen
12/15/2005WO2005117963A1 Medical uses of carrier conjugates of non-human tnf-peptides
12/15/2005WO2005117962A1 Preservation by vaporization
12/15/2005WO2005117961A1 Sars virus vaccine with adenovirus carrier and preparation method thereof , and use of sars virus s gene for preparation of vaccine
12/15/2005WO2005117960A1 Sars dna vaccine and its preparing method, the use of spike gene of coronavirus for vaccine
12/15/2005WO2005117959A2 NEEDLE-FREE ADMINISTRATION OF FeLV BVACCINES
12/15/2005WO2005117958A1 Vaccine compositions comprising virosomes and a saponin adjuvant
12/15/2005WO2005117957A2 Compositions and methods involving o-acetylated group b streptococcus capsular polysaccharides
12/15/2005WO2005117956A2 Neisserial vaccines
12/15/2005WO2005117931A2 Glut1 transporters expressed in cancer cells
12/15/2005WO2005117877A1 Treatment with irinotecan (cpt-11) and an egfr-inhibitor
12/15/2005WO2005107785A3 Human complement c3 derivates with cobra venom factor-like function
12/15/2005WO2005099752A9 Antigen delivery vectors and constructs
12/15/2005WO2005084208A3 A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
12/15/2005WO2005080985A3 Methods and compositions for detecting and treating autoimmune diseases
12/15/2005WO2005079848A3 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
12/15/2005WO2005079506A3 Systemic immune activation method using nucleic acid-lipid complexes
12/15/2005WO2005077093A3 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
12/15/2005WO2005075666A3 Diagnostics and therapeutics for diseases associated with puromycin sensitive aminopeptidase npepps (npepps)
12/15/2005WO2005060541A3 Peptides and methods for inducing cellular resistance to infection
12/15/2005WO2005058359A3 Method for neutralizing effects of crp for increasing immune reactions to hiv
12/15/2005WO2005056572A3 Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof
12/15/2005WO2005048914A3 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
12/15/2005WO2005039501A3 Immunogenic composition and method of developing a vaccine based on fusion protein
12/15/2005WO2005033267A3 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof
12/15/2005WO2005032582A8 Immunogenic compositions for streptococcus pyogenes
12/15/2005WO2005027774A3 Method and apparatus for preventing allergies
12/15/2005WO2004096989A9 Single chain antigen-binding polypeptides for polymer conjugation
12/15/2005WO2004091507A3 Optimal polyvalent vaccine for cancer
12/15/2005WO2004066931A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
12/15/2005WO2004064787A3 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
12/15/2005WO2004047757A3 Diagnosing and treating hematopoietic cancers
12/15/2005WO2004041842A3 Epitopes of hepatitis c virus
12/15/2005WO2003062370A3 Multimeric proteins and methods of making and using same
12/15/2005WO2002083921A8 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
12/15/2005WO2002083855A3 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
12/15/2005US20050277764 Nucleic acid sequence encoding a mammalian MDM2 binding protein for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein
12/15/2005US20050277609 Immunostimulatory nucleic acid molecules
12/15/2005US20050277605 Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation
12/15/2005US20050277604 Immunostimulatory nucleic acid molecules
12/15/2005US20050277161 Phosphopeptide antigens associated with MHC molecules
12/15/2005US20050277127 High-throughput method of DNA immunogen preparation and immunization
12/15/2005US20050277112 Novel therapeutic processes for treating infectious agents using same epitope specific antigens, and useful compositions therefor
12/15/2005US20050276822 cancer vaccines; grows as an epithelial, adherent monolayer culture; does not overexpress estrogen receptors; overexpresses her2/neu; sensitive in vitro to cyclophosphamide (4HC), etoposide and taxol; resistant in vitro to carboplatin; demonstrates karyotypic abnormalities
12/15/2005US20050276821 Antigen protein and nucleic acid coding for said protein
12/15/2005US20050276819 Helicobacter pylori CAI antigen
12/15/2005US20050276818 Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
12/15/2005US20050276817 Rhodococcus equi mutants and vaccines comprising same
12/15/2005US20050276816 Infectious DNA as a vaccine against west nile and other flavivirues
12/15/2005US20050276814 Streptococcus pneumoniae proteins and nucleic acid molecules
12/15/2005US20050276813 Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
12/15/2005US20050276812 Antibody-drug conjugates and methods
12/15/2005US20050276811 Natural IgM antibodies and inhibitors thereof
12/15/2005US20050276810 Cis-4-hydroxy-L-proline (CHP) together with bevacizumab for targeted treatment of cell proliferative disorders
12/15/2005US20050276809 comprising antibodies that specifically bind caspase-8 as inhibitors; cancer; activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy
12/15/2005US20050276808 Administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist, renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma
1 ... 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 ... 1823